Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2012-08-01 Interim / Quarterly Rep…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
2012 HY management report - NL - final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halfjaarlijks financieel verslag 2012' (Half-year financial report 2012) and contains detailed financial tables, including income statements, balance sheet summaries, and cash flow data for the six-month period ending June 30, 2012. It provides a comprehensive management review of the first semester. As it contains substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2012
2012-08-01 Dutch
UCB Launches Neupro® in the U.S. to treat Parkinson’s Disease and Restless Legs Syndrome
Regulatory Filings Classification · 95% confidence The document is a press release dated July 16, 2012, announcing the launch and availability of the drug Neupro® (Rotigotine Transdermal System) in U.S. pharmacies for Parkinson's Disease and Restless Legs Syndrome. It details clinical trial results, safety information, and product indications. This type of announcement, which communicates significant business or product news outside of mandatory periodic financial reports (like 10-K or IR), typically falls under a general press release or regulatory announcement category. Since it is not a formal financial report (10-K, IR, MRQ), a transcript (CT), or a specific management/board change (MANG), the most appropriate classification is the general regulatory/news announcement category, RNS (Regulatory Filings), as it serves as a public disclosure of a major business event. It is not an Earnings Release (ER) as it focuses on product launch, not period results. It is not an Investor Presentation (IP) as it is structured as a press release. Given the nature of the announcement (product launch/availability), RNS is the best fit among the provided options for a non-standard, material corporate disclosure.
2012-07-16 English
UCB lance Neupro® aux États-Unis pour le traitement de la maladie de Parkinson et du syndrome des jambes sans repos
Regulatory Filings Classification · 90% confidence The document is a press release dated July 16, 2012, announcing the availability of the drug Neupro® in the US market for Parkinson's disease and Restless Legs Syndrome. It details clinical trial results, safety information, and background on the diseases. This type of announcement, focusing on a specific product launch or significant business event, is typically classified as a general corporate announcement or press release. Since there is no specific category for a 'Product Launch Announcement' or 'Press Release' that isn't tied to earnings (ER) or capital changes (CAP), and it is not a formal regulatory filing like a 10-K or IR, the most appropriate general category is 'Regulatory Filings' (RNS) as a fallback for significant, non-standard corporate news, or potentially 'Earnings Release' (ER) if it were tied to quarterly results, which it is not. Given the content is a detailed product announcement, it is best classified as a general regulatory/corporate announcement, fitting the 'RNS' definition for miscellaneous filings that do not fit elsewhere, although it strongly resembles an Investor Presentation (IP) in structure, it lacks the typical investor deck format. However, since it is a formal announcement of a business event (product availability), and not a report itself, RNS is the safest fallback, or potentially a very detailed ER if we stretch the definition, but RNS is better for general news releases.
2012-07-16 French
UCB introduceert Neupro® in de VS voor de behandeling van de ziekte van Parkinson en het rustelozebenensyndroom
Earnings Release Classification · 90% confidence The document is a press release dated July 16, 2012, announcing that UCB's drug Neupro® (Rotigotine Transdermal System) is now available in US pharmacies for treating Parkinson's disease and Restless Legs Syndrome. It details clinical trial data, efficacy, side effects, and important safety information for the US and EU markets. This content structure—a formal announcement of a product launch/update, including clinical efficacy and safety warnings—is characteristic of an Earnings Release (ER) or a general press release related to business operations, but it is not a comprehensive annual report (10-K), an interim report (IR), or a specific regulatory filing like a DEF 14A or DVA. Since it is an initial announcement of results/availability, the most fitting category among the provided options is 'Earnings Release' (ER), as these often contain key business updates and data highlights, even if not strictly quarterly earnings figures. Given the context of a major product launch announcement with supporting data, ER is the closest fit for a significant business update announcement. Q3 2012
2012-07-16 Dutch
Acquisition of own shares_ENG (28-06).pdf
Transaction in Own Shares Classification · 99% confidence The document is titled "Acquisition of own shares" and explicitly details transactions where UCB SA/NV bought back (repurchased) 2.5 million shares OTC and acquired an additional 15,000 shares on the Brussels stock exchange. This activity directly relates to the company managing its own equity structure through share repurchases. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. The document length is relatively short (4228 chars), but it contains the substantive details of the transaction rather than just announcing that a report is available, thus it is classified as the transaction report itself.
2012-06-28 English
Acquisition of own shares_FR (28-06).pdf
Transaction in Own Shares Classification · 99% confidence The document title is "Acquisition d'actions propres" (Acquisition of own shares) and the text explicitly details transactions where UCB SA sold and repurchased its own shares (share swap) and acquired additional shares on the stock exchange, which were delivered to employees exercising stock options. This directly relates to the company buying back or selling its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). The document is a regulatory announcement dated June 28, 2012, detailing specific share transactions.
2012-06-28 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.